Evidence map›Paper›PMID 42622368›Full record

ArticleAdvanced healthcare materials2026

Biphasic Co-Delivery of Curcumin and 5-FU using 3D-Printed Dissolving Microneedles for Skin Cancer Therapy.

Rutuja N Meshram, Dimitrios A Lamprou

Abstract read
In one paragraph

Article in Advanced healthcare materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Rutuja N MeshramSchool of Pharmacy, Queen's University Belfast, Belfast, UK.ORCID https://orcid.org/0009-0006-8255-5385
Dimitrios A LamprouSchool of Pharmacy, Queen's University Belfast, Belfast, UK.ORCID https://orcid.org/0000-0002-8740-1661

Funding

Joint Commissioner (Education Branch), Social Welfare - Maharashtra, India CWS/Edu/F.S./2023-24
6 · The paper itself

Abstract

Dissolving microneedle (MN) arrays are a minimally invasive strategy for localized transdermal chemotherapy; however, their translation is limited by drug loading, reproducible dosing, and the difficulty of incorporating chemically distinct drugs into printable matrices. Although MN-mediated delivery of curcumin and 5-fluorouracil (5-FU) has previously been reported using inkjet/coating-based approaches, those systems deposit drug formulations onto preformed solid MNs and are therefore constrained by surface coating uniformity, limited matrix integration, possible drug loss during handling, and less direct control over geometry-dependent dose. Here, we report a distinct one-step DLP 3D-printing strategy in which hydrophilic 5-FU and hydrophobic curcumin are incorporated directly into a single PEGDA/VP photocurable resin before fabrication. The optimized resin enabled high-resolution MN arrays with CAD-defined dimensions, sharp tips, insertion efficiency above 95%, high drug entrapment, and controlled/biphasic release behavior. Importantly, the work demonstrates that curcumin's optical absorbance can be managed through exposure optimization without compromising print fidelity, allowing dual-drug-loaded dissolving MNs to be manufactured directly from the therapeutic resin. These findings establish the system as a formulation-process-performance platform rather than a first report of curcumin/5-FU MN co-delivery, providing a scalable and customizable approach for localized skin-cancer drug delivery that warrants future biological validation.

Indexed as

CurcuminFluorouracilPrinting, Three-DimensionalSkin NeoplasmsAdministration, CutaneousAnimalsHumansMicroneedle Drug DeliveryCurcuminFluorouracil3D printing5‐fluorouracilcurcumindissolving microneedlesskin cancertransdermal drug delivery

Identifiers

PMID42622368
PMCPMC13586632

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.